Prostate cancer treated by anti-androgens: Is sexual function preserved?

British Journal of Cancer

Volumn 82, Issue 2, 2000, Pages 283-290

  Schroder F H ^a   Collette, L ^a   De Reijke, T M ^a   Whelan, P ^a   Pavone Macaluso, M ^b   Mattelaer, J ^b   van Velthoven, R P F ^b   Newling, D W W ^b   Studer, U E ^b   Brausi, M ^c   Akdas, A ^b   Denis, L ^b   de Pauw, M ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE   (Belgium)

^c Cardiology Unit Ramazzini Hospital   (Italy)

Author keywords

Anti androgens; Prostate cancer; Sexual function

Indexed keywords

ANTIANDROGEN; CYPROTERONE ACETATE; FLUTAMIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GYNECOMASTIA; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; MULTICENTER STUDY; PENIS ERECTION; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEXUAL BEHAVIOR;

EID: 0033954129     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.0916     Document Type: Article

References (26)

1. Agresti A (1990) Categorical Data Analysis. John Wiley & Sons: New York
2. Ahrens R (1990) Erfahrungen mit Cyproteronacetat bei Patienten mit Sexualdelinquenz. In: Zur Therapie von sexuell Devianten, Wille R, Schumacher W and Andrzejak N (eds). pp. 58-81. Diesbach Verlag: Berlin
3. Armitage P (1995) Test for linear trend in proportions and frequencies. Biometrics 11: 375-386
4. Blackledge GP (1996) High-dose bicalutamide monotherapy for the treatment of prostate cancer. Urology 47: 44-47
5. Boccon-Gibod L (1998) Are non-steroidal antiandrogens appropriate as monotherapy in advanced prostate cancer? Eur Urol 33: 159-162
6. Dalesio O, Schröder FH, Peto R, and the Prostate Cancer Trialists' Collaborative Group (1995) Maximal androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3289 deaths in 5710 patients. Lancet 346: 265-269
7. Diokno AC, Brown MB and Herzog AR (1990) Sexual function in the elderly. Arch Intern Med 150: 197
8. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM, Bueschen AJ and Lowe BA (1998) Bilateral orchiectomy with or without Flutamide for metastatic prostate cancer. N Engl J Med 339: 1036-1042
9. Ellis WJ and Grayhack JT (1963) Sexual function in aging males after orchiectomy and estrogen therapy. J Urol 89: 895-899
10. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ McKinlay JB (1994) Impotence and its medical and psychosocial correlates: results of the Massachusettes male aging study. J Urol 151: 54-61
11. Fitzpatrick JM, Kirby RS, Krane RJ, Adolfsson J, Newling DWW and Goldstein I (1998) Sexual dysfunction associated with the management of prostate cancer. Eur Urol 33: 513-522
12. Frenken J (1978) SBS seksualiteit belevingsshalen; vragenlijst voor de man. In: Frenken J and Vennix P (eds). pp. 20. Swets & Zeitlinger: Lisse
13. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD and Akakura K (1995) Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 45: 839-845
14. Helgason AR, Arver S, Adolfsson J, Dickman P, Granath F and Steineck G (1998) 'Potency'. The validation of information from a self-administrated questionnaire using objective measurements of night-time erections and test-retest reliability. Br J Urol 81: 135-141
15. Jacobi GH, Altwein JE, Kurth KH, Basting R and Hohenfellner R (1980) Treatment of advanced prostatic cancer with parenteral Cyproterone acetate: a phase III randomised trial. Br J Urol 52: 208-215
16. Kapłan EL and Meier P (1958) Non parametric estimation from incomplete observations. J Am Statist Ass 583: 457-481
17. Lund F and Rasmussen F (1988) Flutamide versus Stilbestrol in the management of advanced prostatic cancer. Br J Urol 61: 140-142
18. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170
19. Morley JE (1988) Impotence in older men. Hospital Practice 23: 139
20. Pavone-Macaluso M, Voogt HJ de, Viggiano G, Barasolo E, Lardennois B, de Pauw M and Sylvester R (1986) Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 136: 624-631
21. Robinson MRG, Smith PH, Richards B, Newling DWW, Pauw M de and Sylvester R (1995) The final analysis of the EORTC Genito-Urinary Group Phase III clinical trial (Protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol 28: 273-283
22. Schröder FH, Whelan P, Kurth KH, Sylvester R, de Pauw M and members of the EORTC Genitourinary Group (1997) Antiandrogens as monotherapy for metastatic prostate cancer: a preliminary report on EORTC protocol 30892. In: Recent Advances in Prostate Cancer and BPH, Proceedings of the IV Congress on Progress and Controversies in Oncological Urology (PACIOU IV), held in Rotterdam, The Netherlands, 11-13 April 1996. Schröder FH (ed), pp. 141-146, Parthenon: New York
23. Sogani PC, Minoo R, Vagaiwala R and Whitmore WS (1984) Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer 54: 744-750
24. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L and Leinonen J (1994) Serum concentrations of prostate specific antigen and its complex with 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 344: 1594-1598
25. The Medical Research Council Prostate Cancer Working Party Investigators Group (1997) Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 79: 235-246
26. Voogt HJ de, Studer U, Schröder FH, Klijn JG, Pauw M de, Sylvester R and members of the EORTC Genito-Urinary Tract Cancer Cooperative Group (1998) Maximum androgen blockade using LHRH agonist Buserelin in combination with short-term (two weeks) or long-term (continuous) Cyproterone-Acetate (CPA) is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. (Final analysis of EORTC GU group trial 30843.) Eur Urol 33: 152-158